Pegfilgrastim to help Kyowa Kirin weather biosimilar G-CSFs?
This article was originally published in Scrip
Executive Summary
In a move that should help it cope over the longer term with competition from newly launched biosimilar filgrastims in Japan, Kyowa Hakko Kirin has filed for the approval in this market of KRN125 (pegfilgrastim), its long-acting form of the granulocyte colony-stimulating factor (G-CSF).